BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 4, 2005
View Archived Issues
Kos Enters Cardio Area, Gets Biovail Products For $104M
Getting a stronger foothold in the cardiovascular therapeutic area, Kos Pharmaceuticals Inc. paid $104 million in cash to Biovail Corp. for U.S. sales and marketing rights to Cardizem LA. (BioWorld Today)
Read More
InKine Files NDA For Bowel Cleansing Product INKP-102
Read More
Combo-Chemo Approach Nets $40M In VC Money For Celator
Read More
Genmab Licenses HuMax-TAC To Serono In Deal Worth Up To $40M
Read More
BioShield II Introduced By Bipartisan Group In Senate
Read More
Correction
Read More
Other News To Note
Read More